Navigation Links
Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants

Retrospective Chart Review in 10 Geographic Regions throughout the United States Presented at Pediatric Academic Societies (PAS) Annual Meeting

HONOLULU, May 5 /PRNewswire/ -- MedImmune announced today that the company presented results from a retrospective chart review that evaluated the use of Synagis(R) (palivizumab) as a preventive measure against respiratory syncytial virus (RSV) disease in high-risk infants. RSV is a leading cause of viral respiratory infection among preterm infants.

Approximately 4,000 medical records from premature infants born at 32-to-35 weeks gestational age were reviewed. Fifty percent of those infants received Synagis. RSV prophylaxis was requested, but not administered in about one quarter of these infants. This group was found to have an RSV hospitalization rate of 8.3 percent, which was almost three times the rate of RSV hospitalization among those infants whose physicians did not request RSV prophylaxis (2.9 percent).

"These data support our position that pediatricians should have the final say in the diagnosis and care of their high-risk patients," said Jessie Groothuis, M.D., lead author of the study and MedImmune vice president, medical and scientific affairs, infectious disease. "Our findings indicate that after nearly 10 years of use of Synagis, the clinical judgment and experience of physicians serve to identify infants at high risk of RSV hospitalization, and should be relied upon to ensure patients get proper care."

This retrospective chart review, conducted in 10 geographic regions across the United States, included 376 physicians from 2005 to 2006. Data were presented at a poster session at the Pediatric Academic Societies (PAS) Annual Meeting being held this week in Honolulu, HI.

About Synagis

Synagis (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) can also occur.

Please see complete prescribing information at

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
2. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
3. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
6. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
9. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
10. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Post Your Comments:
(Date:12/1/2015)... December 1, 2015 --> ... research report "Nucleic Acid Labeling Market by Product (Reagents ... Random Primer, In Vitro Transcription, Reverse Transcription, End Labeling), ... MarketsandMarkets, The global market is expected to reach USD ... 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... , Dec. 01, 2015 ... announced the addition of the ... Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, ... report to their offering. --> ... addition of the "2016 Europe ...
(Date:12/1/2015)... ANGELES , Dec. 1, 2015 CytRx ... development company specializing in oncology, today announced that it ... the company,s pivotal global Phase 3 clinical trial of ... (STS). Enrollment was originally estimated to be completed in Q1 ... being conducted under a Special Protocol Assessment from the ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... of Excellence (BHCOE) today announced that the organization has awarded Education and Developmental ... with a Distinguished Award. The award celebrates exceptional special needs providers that excel ...
(Date:12/1/2015)... MA (PRWEB) , ... December 01, 2015 , ... Lutronic, ... release of Clarity, the latest addition to the devices for sale in the United ... 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... XTC ... selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s largest ... CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, ...
(Date:12/1/2015)... ... , ... Nurotron Biotechnology Co., Ltd., maker of cochlear implant systems, has won ... order will be from the China Disabled Persons’ Federation, a central government association, for ... for children and adults suffering from severe and profound hearing loss . The ...
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... Unified Contact Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation ... deploy and support Cisco Unified Contact Center solutions targeted to the high-end enterprise ...
Breaking Medicine News(10 mins):